Investigation the Effect of the Exposure Time of Docetaxel on MCF-7 Cell Line: An In-Vitro Assessment

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Medical Physics and Biomedical Engineering, School of Medicine AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Department of Medical Physics and Biomedical Engineering, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Assistant Professor, Department of Anatomical Sciences, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Assistant Professor, Department of Radiation and Oncology, Seyed Al-Shohada Hospital, Isfahan University of Medical Science, Isfahan, Iran

Abstract

Background: Chemotherapy is one of the most applied methods in cancer treatment. Selection of the most effective cytostatic drug for cancer treatment is an important step in chemotherapy. Docetaxel is a drug that has especial effect when it combined with ionization radiation. The main effect of docetaxel is to block the cell cycle at the G2/M phase which has special sensitivity to the ionizing radiation. Different factors can impress the combination effect of their usage; one of them is exposure time of docetaxel with cells. In this study, we provided an experimental study about different exposure-time-induced effects of docetaxel on MCF-7 cells.Methods: We divided cells in three groups of control and 1 and 2 which were treated with different concentration of docetaxel for 5 or 24 hour, respectively. In-vitro cell viability tests were done to investigate their effect on MCF-7 cell line for 24, 48 and 72 hours after the experiment.Findings: The cytotoxicity was depended on the concentration of docetaxel. There was a significant decrease in cell viability at all concentration, especially in high concentrations for group 2 compared with group 1 which indicated time- and dose- dependency of the drug.Conclusion: Our study demonstrated that exposure time has an important effect on viability of the cells were treated with docetaxel. This phenomenon can affect treatment of cancer, especially in the field of combination therapy.

Keywords

References

  1. Akbari A, Razzaghi Z, Homaee F, Khayamzadeh M, Movahedi M, Akbari ME. Parity and breastfeeding are preventive measures against breast cancer in Iranian women. Breast Cancer 2011; 18(1): 51-5.
  2. Huo D, Adebamowo CA, Ogundiran TO, Akang EE, Campbell O, Adenipekun A, et al. Parity and breastfeeding are protective against breast cancer in Nigerian women. Br J Cancer 2008; 98(5): 992-6.
  3. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20(12): 2812-23.
  4. Liu B, Staren ED, Iwamura T, Appert HE, Howard JM. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J Surg Res 2001; 99(2): 179-86.
  5. Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 2005; 10(9): 665-85.
  6. Nogales E, Wolf SG, Downing KH. Structure of the alpha beta tubulin dimer by electron crystallography. Nature 1998; 391(6663): 199-203.
  7. Clemons M, Leahy M, Valle J, Jayson G, Ranson M, Hayes S, et al. Review of recent trials of chemotherapy for advanced breast cancer: studies excluding taxanes. Eur J Cancer 1997; 33(13): 2171-82.
  8. Wilson L, Jordan MA. Microtubule dynamics: taking aim at a moving target. Chem Biol 1995; 2(9): 569-73.
  9. Qi C, Zhu YJ, Zhao XY, Lu BQ, Tang QL, Zhao J, et al. Highly stable amorphous calcium phosphate porous nanospheres: microwave-assisted rapid synthesis using ATP as phosphorus source and stabilizer, and their application in anticancer drug delivery. Chemistry 2013; 19(3): 981-7.
  10. Yvon AM, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 1999; 10(4): 947-59.
  11. Crown J. Docetaxel: overview of an active drug for breast cancer. Oncologist 2001; 6(Suppl 3): 1-4.
  12. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008; 1785(2): 96-132.
  13. Kumar N. Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 1981; 256(20): 10435-41.
  14. Hernandez-Vargas H, Palacios J, Moreno-Bueno G. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene 2007; 26(20): 2902-13.
  15. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999; 36(2): 99-114.
  16. Tishler RB, Norris CM, Jr., Colevas AD, Lamb CC, Karp D, Busse PM, et al. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer 2002; 95(7): 1472-81.
  17. Calais G, Bardet E, Sire C, Alfonsi M, Bourhis J, Rhein B, et al. Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial. Int J Radiat Oncol Biol Phys 2004; 58(1): 161-6.
  18. Colevas AD, Busse PM, Norris CM, Fried M, Tishler RB, Poulin M, et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 1998; 16(4): 1331-9.
  19. Kovacs AF, Mose S, Bottcher HD, Bitter K. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Strahlenther Onkol 2005; 181(1): 26-34.
  20. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357(17): 1695-704.
  21. Steel GG, McMillan TJ, Peacock JH. The radiobiology of human cells and tissues. In vitro radiosensitivity. The picture has changed in the 1980s. Int J Radiat Biol 1989; 56(5): 525-37.
  22. Balkman CE, Gieger TL, Zgola MM, Lewis LD, McEntee MC. In vitro characterization of docetaxel as a radiosensitizer in canine and feline cancer cell lines. Open J Vet Med 2012; 2(4): 285-92.
  23. Fabbri F, Carloni S, Brigliadori G, Zoli W, Lapalombella R, Marini M. Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: a cytometric study. BMC Cell Biol 2006; 7: 6.
Journal of Isfahan Medical School
Volume 33, Issue 345 - Serial Number 345
July and August 2015
Pages 1272-1280

Files

History

  • Receive Date: 01 August 2015
  • Revise Date: 05 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics